164 related articles for article (PubMed ID: 30987825)
1. Identification of a potent inhibitor of type II secretion system from Pseudomonas aeruginosa.
Swietnicki W; Czarny A; Antkowiak L; Zaczynska E; Kolodziejczak M; Sycz J; Stachowicz L; Alicka M; Marycz K
Biochem Biophys Res Commun; 2019 Jun; 513(3):688-693. PubMed ID: 30987825
[TBL] [Abstract][Full Text] [Related]
2. Development, Optimization, and Validation of a High Throughput Screening Assay for Identification of Tat and Type II Secretion Inhibitors of
Massai F; Saleeb M; Doruk T; Elofsson M; Forsberg Å
Front Cell Infect Microbiol; 2019; 9():250. PubMed ID: 31355152
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Protein-Protein Interface Inhibitors Allow Efficient Inhibition of Type III Secretion Machinery and
Ngo TD; Plé S; Thomas A; Barette C; Fortuné A; Bouzidi Y; Fauvarque MO; Pereira de Freitas R; Francisco Hilário F; Attrée I; Wong YS; Faudry E
ACS Infect Dis; 2019 Nov; 5(11):1843-1854. PubMed ID: 31525902
[No Abstract] [Full Text] [Related]
4. A Computational workflow for the identification of the potent inhibitor of type II secretion system traffic ATPase of Pseudomonas aeruginosa.
Arifuzzaman M; Mitra S; Jahan SI; Jakaria M; Abeda T; Absar N; Dash R
Comput Biol Chem; 2018 Oct; 76():191-201. PubMed ID: 30053700
[TBL] [Abstract][Full Text] [Related]
5. Impact of Type III Secretion Effectors and of Phenoxyacetamide Inhibitors of Type III Secretion on Abscess Formation in a Mouse Model of Pseudomonas aeruginosa Infection.
Berube BJ; Murphy KR; Torhan MC; Bowlin NO; Williams JD; Bowlin TL; Moir DT; Hauser AR
Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807906
[No Abstract] [Full Text] [Related]
6. Targeting the Type Three Secretion System in Pseudomonas aeruginosa.
Anantharajah A; Mingeot-Leclercq MP; Van Bambeke F
Trends Pharmacol Sci; 2016 Sep; 37(9):734-749. PubMed ID: 27344210
[TBL] [Abstract][Full Text] [Related]
7.
Martínez E; Orihuela CJ; Campos-Gomez J
J Bacteriol; 2022 Jul; 204(7):e0011422. PubMed ID: 35658521
[TBL] [Abstract][Full Text] [Related]
8. Unraveling the Self-Assembly of the
Douzi B; Trinh NTT; Michel-Souzy S; Desmyter A; Ball G; Barbier P; Kosta A; Durand E; Forest KT; Cambillau C; Roussel A; Voulhoux R
mBio; 2017 Oct; 8(5):. PubMed ID: 29042493
[TBL] [Abstract][Full Text] [Related]
9. The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo.
Uusitalo P; Hägglund U; Rhöös E; Scherman Norberg H; Elofsson M; Sundin C
J Antibiot (Tokyo); 2017 Aug; 70(9):937-943. PubMed ID: 28588224
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa Antivirulence Strategies: Targeting the Type III Secretion System.
Goldberg JB; Crisan CV; Luu JM
Adv Exp Med Biol; 2022; 1386():257-280. PubMed ID: 36258075
[TBL] [Abstract][Full Text] [Related]
11. Derivatives of plant phenolic compound affect the type III secretion system of Pseudomonas aeruginosa via a GacS-GacA two-component signal transduction system.
Yamazaki A; Li J; Zeng Q; Khokhani D; Hutchins WC; Yost AC; Biddle E; Toone EJ; Chen X; Yang CH
Antimicrob Agents Chemother; 2012 Jan; 56(1):36-43. PubMed ID: 21968370
[TBL] [Abstract][Full Text] [Related]
12. Structure-guided disruption of the pseudopilus tip complex inhibits the Type II secretion in Pseudomonas aeruginosa.
Zhang Y; Faucher F; Zhang W; Wang S; Neville N; Poole K; Zheng J; Jia Z
PLoS Pathog; 2018 Oct; 14(10):e1007343. PubMed ID: 30346996
[TBL] [Abstract][Full Text] [Related]
13. Direct interactions between the secreted effector and the T2SS components GspL and GspM reveal a new effector-sensing step during type 2 secretion.
Michel-Souzy S; Douzi B; Cadoret F; Raynaud C; Quinton L; Ball G; Voulhoux R
J Biol Chem; 2018 Dec; 293(50):19441-19450. PubMed ID: 30337370
[TBL] [Abstract][Full Text] [Related]
14. A Structure-Function-Inhibition Analysis of the
Moir DT; Bowlin NO; Berube BJ; Yabut J; Mills DM; Nguyen GT; Aron ZD; Williams JD; Mecsas J; Hauser AR; Bowlin TL
J Bacteriol; 2020 Aug; 202(18):. PubMed ID: 32601072
[TBL] [Abstract][Full Text] [Related]
15. Structure and oligomerization of the periplasmic domain of GspL from the type II secretion system of Pseudomonas aeruginosa.
Fulara A; Vandenberghe I; Read RJ; Devreese B; Savvides SN
Sci Rep; 2018 Nov; 8(1):16760. PubMed ID: 30425318
[TBL] [Abstract][Full Text] [Related]
16. Pseudomonas aeruginosa Magnesium Transporter MgtE Inhibits Type III Secretion System Gene Expression by Stimulating
Chakravarty S; Melton CN; Bailin A; Yahr TL; Anderson GG
J Bacteriol; 2017 Dec; 199(23):. PubMed ID: 28847924
[No Abstract] [Full Text] [Related]
17. Targeting the Type II Secretion System: Development, Optimization, and Validation of a High-Throughput Screen for the Identification of Small Molecule Inhibitors.
Waack U; Johnson TL; Chedid K; Xi C; Simmons LA; Mobley HLT; Sandkvist M
Front Cell Infect Microbiol; 2017; 7():380. PubMed ID: 28894700
[TBL] [Abstract][Full Text] [Related]
18. Attenuation of
Sharma P; Elofsson M; Roy S
Virulence; 2020 Dec; 11(1):795-804. PubMed ID: 32507000
[TBL] [Abstract][Full Text] [Related]
19. Structural and functional characterization of type three secretion system ATPase PscN and its regulator PscL from Pseudomonas aeruginosa.
Halder PK; Roy C; Datta S
Proteins; 2019 Apr; 87(4):276-288. PubMed ID: 30561072
[TBL] [Abstract][Full Text] [Related]
20. The Impact of ExoS on
Kroken AR; Chen CK; Evans DJ; Yahr TL; Fleiszig SMJ
mBio; 2018 May; 9(3):. PubMed ID: 29717012
[No Abstract] [Full Text] [Related]
[Next] [New Search]
